ZYME
BEARISH
$27.43
Live
Zymeworks Inc. · NASDAQ
Target $40.08
(+46.1%)
$10.86
52W Range
$28.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 24, 2026
Market cap
$2.04B
P/E
N/A
ROE
-26.7%
Profit margin
-76.6%
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ZYME exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a failing financial trajectory. Despite a strong liquidity position (Current Ratio 5.88) and low debt, the company has suffered a catastrophic revenue collapse of -91.90% YoY. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $4.67M in shares. The valuation is speculative, trading at a high Price/Sales multiple of 19.23 despite negative margins and shrinking top-line growth.
Key Strengths
Very low Debt/Equity ratio (0.07)
Strong short-term liquidity with a Current Ratio of 5.88
High analyst target price ($40.08) suggesting potential pipeline catalysts
Strong 1-year price appreciation (+120.3%)
Low overall debt burden
Key Risks
Catastrophic revenue decline of -91.90% YoY
Severe operational inefficiency with an operating margin of -1755.55%
Critical Piotroski F-Score (1/9) signaling poor financial health
Aggressive insider selling by the CEO and other officers
Extreme valuation premiums (P/S 19.23, P/B 7.63) without supporting earnings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
10
30
20
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score 1/9, Revenue Growth -91.90%, Insider Selling, High P/S Ratio
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- P/S of 19.23 is excessive for negative growth
- P/B of 7.63 indicates high premium over assets
- No Graham Number available due to lack of earnings
Future
10/100
Ref Growth rates
Positives
- Analyst target price suggests future pipeline success
Watchpoints
- Revenue growth is crashing (-91.90%)
- EPS growth is deeply negative
Past
30/100
Ref Historical trends
Positives
- Strong 1-year and 6-month price momentum
Watchpoints
- Consistent history of quarterly losses
- Recent sharp decline in revenue
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Excellent Current Ratio (5.88)
- Minimal Debt/Equity (0.07)
Watchpoints
- Piotroski F-Score of 1/9 is a critical warning sign
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$27.43
Analyst Target
$40.08
Upside/Downside
+46.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ZYME and closest competitors.
Updated 2026-04-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ZYME
Zymeworks Inc.
Primary
|
-3.4% | +180.8% | +120.3% | +57.5% | +16.2% | +0.8% |
|
AORT
Artivion, Inc.
Peer
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
ADPT
Adaptive Biotechnologies Corporation
Peer
|
-69.3% | +61.8% | +83.7% | +4.4% | -15.7% | -11.4% |
|
RXRX
Recursion Pharmaceuticals, Inc.
Peer
|
-86.5% | -36.4% | -31.3% | -35.5% | +13.9% | +15.2% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+28.4% | +28.4% | +17.7% | -41.4% | -10.7% | -8.5% |
ZYM
Zymeworks Inc.
Primary
5Y
-3.4%
3Y
+180.8%
1Y
+120.3%
6M
+57.5%
1M
+16.2%
1W
+0.8%
AOR
Artivion, Inc.
Peer
5Y
+72.4%
3Y
+236.1%
1Y
+40.5%
6M
+37.0%
1M
-8.2%
1W
-0.8%
ADP
Adaptive Biotechnologies Corporation
Peer
5Y
-69.3%
3Y
+61.8%
1Y
+83.7%
6M
+4.4%
1M
-15.7%
1W
-11.4%
RXR
Recursion Pharmaceuticals, Inc.
Peer
5Y
-86.5%
3Y
-36.4%
1Y
-31.3%
6M
-35.5%
1M
+13.9%
1W
+15.2%
AAP
Ascentage Pharma Group Internat
Peer
5Y
+28.4%
3Y
+28.4%
1Y
+17.7%
6M
-41.4%
1M
-10.7%
1W
-8.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
34.84
PEG Ratio
N/A
P/B Ratio
7.63
P/S Ratio
19.23
EV/Revenue
17.1
EV/EBITDA
-21.37
Market Cap
$2.04B
Profitability
Profit margins and return metrics
Profit Margin
-76.56%
Operating Margin
-1755.55%
Gross Margin
-29.29%
ROE
-26.72%
ROA
-14.29%
Growth
Revenue and earnings growth rates
Revenue Growth
-91.9%
Earnings Growth
N/A
Q/Q Revenue Growth
-91.9%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
5.88
Strong
Quick Ratio
5.52
Excellent
Cash/Share
$3.1
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-1754.3%
Net Margin
-1638.5%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.29x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
107%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-02
$-0.55
-59.5% surprise
2025-11-06
$-0.26
+17.8% surprise
2025-08-07
$0.03
+106.4% surprise
Healthcare Sector Comparison
Comparing ZYME against 528 companies in the Healthcare sector
(28 bullish, 156 neutral, 344 bearish)
Return on Equity (ROE)
-26.72%
This Stock
vs
-92.94%
Sector Avg
-71.2%
(Below Avg)
Profit Margin
-76.56%
This Stock
vs
-16.56%
Sector Avg
+362.4%
(Superior)
Debt to Equity
0.07
This Stock
vs
2.75
Sector Avg
-97.5%
(Less Debt)
Revenue Growth
-91.9%
This Stock
vs
131.76%
Sector Avg
-169.8%
(Slower)
Current Ratio
5.88
This Stock
vs
4.62
Sector Avg
+27.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ZYME
Zymeworks Inc.
|
BEARISH | $2.04B | - | -26.7% | -76.6% | $27.43 | |
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | Compare |
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.03B | - | -27.8% | -21.5% | $13.17 | Compare |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
NEUTRAL | $2.0B | - | -59.5% | -% | $3.78 | Compare |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.09B | - | -159.6% | -296.8% | $22.32 | Compare |
ZYME
Zymeworks Inc.
BEARISH
Mkt Cap
$2.0B
P/E
-
ROE
-26.7%
Price
$27.43
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-12 | SMITH JEFFREY T L MD, FRCP | Officer | Sale | 9,310 | $211,090 |
| 2026-01-12 | SMITH JEFFREY T L MD, FRCP | Officer | Stock Award | 17,666 | - |
| 2026-01-12 | GALBRAITH KENNETH HARRY | Chief Executive Officer | Sale | 30,424 | $689,819 |
| 2026-01-12 | GALBRAITH KENNETH HARRY | Chief Executive Officer | Stock Award | 64,000 | - |
| 2026-01-12 | MOORE PAUL ANDREW | Officer | Sale | 9,560 | $216,759 |
| 2026-01-12 | MOORE PAUL ANDREW | Officer | Stock Award | 17,666 | - |
| 2026-01-12 | HOLLYWOOD MARK | Chief Operating Officer | Sale | 6,120 | $138,762 |
| 2026-01-12 | HOLLYWOOD MARK | Chief Operating Officer | Stock Award | 17,666 | - |
| 2026-01-06 | PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award | 459 | $11,099 |
| 2026-01-05 | SMITH JEFFREY T L MD, FRCP | Officer | Sale | 10,538 | $264,471 |
| 2026-01-05 | SMITH JEFFREY T L MD, FRCP | Officer | Stock Award | 20,000 | - |
| 2026-01-05 | GALBRAITH KENNETH HARRY | Chief Executive Officer | Sale | 54,343 | $1,363,841 |
| 2026-01-05 | GALBRAITH KENNETH HARRY | Chief Executive Officer | Stock Award | 114,334 | - |
| 2026-01-05 | MOORE PAUL ANDREW | Officer | Sale | 20,110 | $504,699 |
| 2026-01-05 | MOORE PAUL ANDREW | Officer | Stock Award | 37,168 | - |
SMITH JEFFREY T L MD, FRCP
Officer
2026-01-12
9,310 shares
·
$211,090
SMITH JEFFREY T L MD, FRCP
Officer
2026-01-12
17,666 shares
GALBRAITH KENNETH HARRY
Chief Executive Officer
2026-01-12
30,424 shares
·
$689,819
GALBRAITH KENNETH HARRY
Chief Executive Officer
2026-01-12
64,000 shares
MOORE PAUL ANDREW
Officer
2026-01-12
9,560 shares
·
$216,759
MOORE PAUL ANDREW
Officer
2026-01-12
17,666 shares
HOLLYWOOD MARK
Chief Operating Officer
2026-01-12
6,120 shares
·
$138,762
HOLLYWOOD MARK
Chief Operating Officer
2026-01-12
17,666 shares
PATTERSON LEONE D. CPA
Chief Financial Officer
2026-01-06
459 shares
·
$11,099
SMITH JEFFREY T L MD, FRCP
Officer
2026-01-05
10,538 shares
·
$264,471
SMITH JEFFREY T L MD, FRCP
Officer
2026-01-05
20,000 shares
GALBRAITH KENNETH HARRY
Chief Executive Officer
2026-01-05
54,343 shares
·
$1,363,841
GALBRAITH KENNETH HARRY
Chief Executive Officer
2026-01-05
114,334 shares
MOORE PAUL ANDREW
Officer
2026-01-05
20,110 shares
·
$504,699
MOORE PAUL ANDREW
Officer
2026-01-05
37,168 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
10-K
8-K
8-K
DEF 14A
10-Q
ZYME's revenue is primarily derived from strategic collaboration agreements, including upfront payments, R&D funding, and milestone payments. Operating expenses are driven largely by research and development and general administrative costs, with personnel expenses comprising a significant component. The company remains dependent on these strategic partnerships as its primary source of revenue for the foreseeable future.
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
13 analysts
Evercore ISI Group
2026-03-09
Outperform
Outperform
HC Wainwright & Co.
2026-03-06
Buy
Buy
Stifel
2026-03-03
Buy
Buy
Leerink Partners
2026-03-03
Outperform
Outperform
Truist Securities
2025-12-17
Buy
Wells Fargo
2025-12-12
Equal-Weight
Overweight
Citizens
2025-12-03
Market Outperform
B. Riley Securities
2025-11-21
Buy
Buy
Wells Fargo
2025-11-19
Equal-Weight
Equal-Weight
Stifel
2025-11-19
Buy
Buy
Past News Coverage
Recent headlines mentioning ZYME from our newsroom.
Newest → oldest
No matching news yet.